Skip to main content
. Author manuscript; available in PMC: 2020 Jul 13.
Published in final edited form as: Mol Pharm. 2019 Jan 16;16(2):552–560. doi: 10.1021/acs.molpharmaceut.8b00836

Figure 4.

Figure 4.

In vivo whole-body bioluminescence images of ES-2-luc-bearing xenograft mice treated with the following: (a) surgery followed by insertion of an empty disc; (b) surgery followed by insertion of a disc carrying paclitaxel and rapamycin; (c) surgery followed by insertion of a sol–gel carrying paclitaxel and rapamycin; (d) surgery followed by insertion of an empty sol–gel; (e) control (no surgery and no treatment) (A) and in vivo tumor progression calculated based on the bioluminescence signals in ROIs (B) (*p < 0.05).